Edition:
United Kingdom

People: Pulmatrix Inc (PULM.OQ)

PULM.OQ on NASDAQ Stock Exchange Capital Market

0.86USD
17 Sep 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$0.86
Open
$0.87
Day's High
$0.87
Day's Low
$0.85
Volume
7,024
Avg. Vol
56,361
52-wk High
$4.60
52-wk Low
$0.72

Raad, Teofilo 

Mr. Teofilo Raad is Chief Executive Officer, Director of the Company. He has served as the Company’s Chief Business Officer since May 2017 and leads the Company’s commercial and business development efforts. He has more than 20 years of commercial health care and life science leadership experience and most recently served as chief commercial officer at Option Care, where he helped separate the specialty home infusion business unit from Walgreens to create the nation’s largest independent home infusion provider. Prior to that, he was a business unit head at Sunovion with overall responsibility for CNS and respiratory products, including assets in asthma and COPD. During his time at Sunovion, Mr. Raad led multiple products through clinical development to commercialization and implemented new strategic alliances in the US and Japan. Earlier in his career he also gained direct launch experience with Sporanox, Janssen’s oral itraconazole product to treat fungal infections, and brings that experience to the Pulmatrix Pulmazole program. Mr. Raad holds a BS in Business Administration from University of Colorado at Boulder and an MBA from Thunderbird Global School of Global Management.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --